Gland Pharma Signs Strategic CDMO Deal, Targets $90-100 Million Annual Revenue

Pharmaceuticals

9 August 2026 at 6:18 pm

Gland Pharma Signs Strategic CDMO Deal, Targets $90-100 Million Annual Revenue

HyperFast News

Summary

Gland Pharma has secured a strategic Manufacturing and Supply Agreement with a major global pharmaceutical company for sterile injectable products, covering 55 SKUs across three sites. This deal has an annualised revenue potential of $90-100 million upon commercialisation, with revenue generation expected to commence in 2029.

Select what you want to create

Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.

FAQ

Newsroom FAQs

About the public HyperFast News news feed powered by NewsEngine.